Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

A New Era for IFN-α in the Treatment of Philadelphia-negative Chronic Myeloproliferative Neoplasms ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the ...

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...